PROGETTO SACS

Progetto FRRB 4969522 - Role of SGLT-2 in the systemic manifestations of ANCA-associated vasculitis (SACS)

Dati del progetto

Principal Investigator

Dr.ssa Monica Locatelli

Ente ospitante

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Area Tematica

Malattie Rare

Data di inizio Progetto

16/12/2024

Data di fine Progetto

15/12/2027

Importo assegnato

494.920,00 €

Tipo Progetto

Individuale

PROJECT AIMS

Anti-neutrophil cytoplasmic antibodies associated vasculitis (AAV) is a group of rare lifethreatening systemic disorders. Its management involves an immunosuppressive-based approach, not always entirely effective, leading to relapses and highlighting the need for newer therapies. Our preliminary and published data indicate that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) can offer immunomodulatory, renal, and cardio-protective benefits. The primary goal of the project is to investigate the role and the pharmacological potential of the SGLT-2 targeting in AAV through a multidisciplinary approach.